LATEST PUBLICATIONS

 2025

• Bilinska A, Ballal S, Bal C, Läppchen T, Pilatis E, Menéndez E, Moon ES, Martin M, Rösch F, Rominger A, Gourni E. (2025).
  Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study.
  European Journal of Nuclear Medicine and Molecular Imaging. 2025/02/26 doi:10.1007/s00259-025-07141-1

• Ballal S, Yadav MP, Satapathy S, Roesch F, Chandekar KR, Martin M, Shakir M, Agarwal S, Rastogi S, Moon ES, Bal C. (2025).
  Long-Term Outcomes in Radioiodine-Resistant Follicular Cell-Derived Thyroid Cancers Treated with [(177)Lu]Lu-DOTAGA.FAPi Dimer Therapy.
  Thyroid. Feb 2025;35(2):188-198. doi:10.1089/thy.2024.0229

• Chopra S, Walia R, Kaur K, Roesch F, Moon ES, Mittal BR, Shukla J. (2025).
  Exploring the FAP-Targeted Therapeutics for Adrenocortical Carcinoma: Choosing the Right Track.
  Clinical Nuclear Medicine. 2025;50(3). doi: 10.1097/RLU.0000000000005483

• Sakir M, Ballal S, Rastogi S, Yadav MP, Roesch F, Chandekar K, Gb P, Tripathi M, Dhiman A, Taggar M, Martin M, Bal C. (2025).
  Head-to-Head Comparison Between [68Ga]Ga-DOTA.SA.FAPi And [18F]F-FDG PET/CT Imaging in Patients With Sarcoma.
  Clin Nucl Med. Jan 29 2025;doi:10.1097/rlu.0000000000005697

 2024

• Läppchen T, Bilinska A, Pilatis E, Menéndez E, Imlimthan S, Moon ES, Afshar-Oromieh A, Rösch F, Rominger A, Gourni E. (2024).
  Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2.
  Molecules. 2024;29(13). doi:10.3390/molecules29133093 

• Tanc M, Filippi N, Van Rymenant Y, Grintsevich S, Pintelon I, Verschuuren M, De Loose J, Verhulst E, Moon ES, Cianni L, Stroobants S, Augustyns K, Roesch F, De Meester I, Elvas F, Van der Veken P. (2024).
  Druglike, (18)F-labeled PET Tracers Targeting Fibroblast Activation Protein.
  J Med Chem. May 9 2024;67(9):7068-7087. doi:10.1021/acs.jmedchem.3c02402

• Chopra S, Mathur Y, Roesch F, Moon ES, Singh H, Kalra N, Duseja A, Mittal BR, Shukla J.(2024).
  68 Ga-DOTA.SA.FAPi PET in Response Assessment After 177 Lu-Microspheres Selective Intra-arterial Radionuclide Therapy for Unresectable Hepatocellular Carcinoma.
  Clin Nucl Med. Oct 1 2024;49(10):e511-e512. doi:10.1097/rlu.0000000000005391

• Chopra S, Mathur Y, Roesch F, Moon ES, Rana N, Irrinki S, Walia R, Duseja A, Singh H, Kumar R, Shukla J, Mittal BR. (2024).
  (68)Ga-DOTA.SA.FAPi as a Versatile Diagnostic Probe for Various Epithelial Malignancies: A Head-to-Head Comparison with (18)F-FDG.
  Acad Radiol. Jan 16 2024. doi:10.1016/j.acra.2023.12.002

• Bao G, Wang Z, Liu L, Zhang B, Song S, Wang D, Cheng S, Moon ES, Roesch F, Zhao J, Yu B, Zhu X. (2024).
  Targeting CXCR4/CXCL12 axis via [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2) with CXCR4 antagonist in triple-negative breast cancer.
  Eur J Nucl Med Mol Imaging 2024. doi: 10.1007/s00259-024-06704-y.

• Ballal S, Yadav MP, Raju S, Roesch F, Martin M, Tripathi M, Bal C. (2024).
  [(177)Lu]Lu-DOTAGA.Glu.(FAPi)(2) Radionuclide Therapy: a New Treatment Option for Patients with Glioblastoma Multiforme.
  Nucl Med Mol Imaging. Feb 2024;58(1):32-34. doi:10.1007/s13139-023-00814-5

• Yadav MP, Ballal S, Martin M, Roesch F, Satapathy S, Moon ES, Tripathi M, Gogia A, Bal C. (2024).
  Therapeutic potential of [(177)Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment.
  Eur J Nucl Med Mol Imaging 51, 805–819 (2024). doi:10.1007/s00259-023-06482-z.

2023 

• Poulie CBM, Shalgunov V, Elvas F, Van Rymenant Y, Moon E-S, Battisti UM, De Loose J, De Meester I, Rösch F, Van Der Veken P, Herth MM. (2023).
  Next generation fibroblast activation protein (FAP) targeting PET tracers – The tetrazine ligation allows an easy and convenient way to 18F-labeled (4-quinolinoyl)glycyl-2-cyanopyrrolidines.
  Pharmaceutics. 2023;15(3)doi:10.3390/pharmaceutics15030776

• Nock BA, Kanellopoulos P, Moon ES, Rouchota M, Loudos G, Ballal S, Yadav MP, Bal C, Mishra P, Sheokand P, Roesch F, Maina T. (2023).
  [(111)In]In/[(177)Lu]Lu-AAZTA(5)-LM4 SST(2)R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results.
  European Journal of Medicinal Chemistry. 2023;262:115862. doi:https://doi.org/10.1016/j.ejmech.2023.115862

• Martin M, Ballal S, Yadav MP, Bal C, Van Rymenant Y, De Loose J, Verhulst E, De Meester I, Van Der Veken P, Roesch F. (2023).
  Novel Generation of FAP Inhibitor-Based Homodimers for Improved Application in Radiotheranostics.
  Cancers (Basel). 2023;15(6)doi:10.3390/cancers15061889

• Lahnif H, Grus T, Salvanou E-A, Deligianni E, Stellas D, Bouziotis P, Rösch F. (2023).
  Old Drug, New Delivery Strategy: MMAE Repackaged.
  International Journal of Molecular Sciences. 2023;24(10):8543. doi: 10.3390/ijms24108543

• Escudero-Castellanos A, Kurth J, Imlimthan S, Menéndez E, Pilatis E, Moon ES, Läppchen T, Rathke H, Schwarzenböck SM, Krause BJ, Rösch F, Rominger A, Gourni E. (2023).
  Translational assessment of a DATA-functionalized FAP inhibitor with facile (68)Ga-labeling at room temperature.
  Eur J Nucl Med Mol Imaging. Jun 7 2023. doi:10.1007/s00259-023-06285-2

• Chopra S, Walia R, Mathur Y, Roesch F, Moon ES, Rana N, Pandey S, Chatterji D, Kumar R, Singh H, Mittal BR, Shukla J. (2023).
  68 Ga-DOTA.SA.FAPI as a Potential, Noninvasive Diagnostic Probe for Recurrent and Metastatic Adrenocortical Carcinoma : A Head-to-Head Comparison With 18F-FDG.
  Clin Nucl Med. Apr 1 2023;48(4):e173-e175. doi:10.1097/rlu.0000000000004563

• Bao G, Zhou H, Zou S, Chen L, Zhang B, Wang Z, Moon ES, Zhao J, Roesch F, Zhu X. (2023).
  Inhibition of Poly(ADP-ribose) Polymerase Sensitizes [177Lu]Lu-DOTAGA.(SA.FAPi)2-Mediated Radiotherapy in Triple-Negative Breast Cancer.
  Molecular Pharmaceutics. 2023/05/01 2023;20(5):2443-2451. doi:10.1021/acs.molpharmaceut.2c01051

• Ballal S, Yadav MP, Roesch F, Satapathy S, Moon ES, Martin M, Wakade N, Sheokand P, Tripathi M, Chandekar KR, Agarwal S, Sahoo RK, Rastogi S, Bal C. (2023).
  Head-to-head comparison of [(68)Ga]Ga-DOTA.SA.FAPi with [(18)F]F-FDG PET/CT in radioiodine-resistant follicular-cell derived thyroid cancers.
  Eur J Nucl Med Mol Imaging. Aug 29 2023. doi:10.1007/s00259-023-06404-z

• Ballal S, Yadav MP, Roesch F, Raju S, Satapathy S, Sheokand P, Moon ES, Martin M, Awarwal S, Tripathi M, Bal C. (2023).
  Head-to-Head Comparison of [(68)Ga]Ga-DOTA.SA.FAPi and [(68)Ga]Ga-DOTANOC Positron Emission Tomography/Computed Tomography Imaging for the Follow-Up Surveillance of Patients with Medullary Thyroid Cancer.
  Thyroid. Jun 1 2023;doi:10.1089/thy.2023.0008

• Ballal S, Yadav MP, Roesch F, Wakade N, Raju S, Sheokand P, Mishra P, Moon ES, Tripathi M, Martin M, Bal C. (2023).
  Head-to-Head Comparison between [(68)Ga]Ga-DOTA.SA.FAPi and [(18)F]F-FDG PET/CT Imaging in Patients with Breast Cancer.
  Pharmaceuticals (Basel). Mar 31 2023;16(4)doi:10.3390/ph16040521

2021

• Ballal, S., Yadav, M. P., Kramer, V., Moon, E. S., Roesch, F., Tripathi, M., Bal, C. (2021).
  A theranostic approach of [⁶⁸Ga]Ga-DOTA.SA.FAPi PET/CT-guided [¹⁷⁷Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy.
  Eur J Nucl Med Mol Imaging, 48(3), 942-944. doi:10.1007/s00259-020-04990-w

• Ballal, S., Yadav, M. P., Moon, E. S., Kramer, V. S., Roesch, F., Kumari, S., & Bal, C. (2021).
  First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [¹⁷⁷Lu]Lu-DOTA.SA.FAPi and [¹⁷⁷Lu]Lu-DOTAGA.(SA.FAPi)2.
  Pharmaceuticals (Basel), 14(12). doi:10.3390/ph14121212

• Lahnif H, Grus T, Pektor S, Greifenstein L, Schreckenberger M, Rösch F. (2021).
  Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach.
  Molecules. Oct 20 2021;26(21). doi:10.3390/molecules26216332

• Imlimthan, S., Moon, E. S., Rathke, H., Afshar-Oromieh, A., Roesch, F., Rominger, A., & Gourni, E. (2021). New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress.
  Pharmaceuticals (Basel), 14(10). doi:10.3390/ph14101023

• Ballal, S., Yadav, M. P., Moon, E. S., Kramer, V. S., Roesch, F., Kumari, S., Bal, C. (2021).
  Biodistribution, pharmacokinetics, dosimetry of [⁶⁸Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [¹⁸F]F-FDG PET/CT in patients with various cancers. Eur J Nucl Med Mol Imaging, 48(6), 1915-1931. doi:10.1007/s00259-020-05132-y

• Moon, E. S., Van Rymenant, Y., Battan, S., De Loose, J., Bracke, A., Van der Veken, P., Roesch, F. (2021).
  In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA(5).SA.FAPi and DOTA.SA.FAPi. Molecules, 26(12). doi:10.3390/molecules26123482

• Grus, T., Lahnif, H., Klasen, B., Moon, E. S., Greifenstein, L., & Roesch, F. (2021).
  Squaric Acid-Based Radiopharmaceuticals for Tumor Imaging and Therapy.
  Bioconjug Chem, 32(7), 1223-1231. doi:10.1021/acs.bioconjchem.1c00305

• Kreppel, B., Gonzalez-Carmona, M. A., Feldmann, G., Küppers, J., Moon, E. S., Marinova, M., Roesch, F., Gaertner, F. C., (2021).
  Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours.
  Nuklearmedizin, 60(5), 344-354. doi:10.1055/a-1521-8604

• Moon, E. S., Ballal, S., Yadav, M. P., Bal, C., Van Rymenant, Y., Stephan, S., Roesch, F. (2021).
  Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time.
  Am J Nucl Med Mol Imaging, 11(6), 476-491.

2020

• Kreppel, B., Gärtner, F. C., Marinova, M., Attenberger, U., Meisenheimer, M., Toma, M., Essler, M., Kristiansen, G., Feldmann, G., Moon, E.S., Roesch, F., Van Der Veken, P., Essler, M. (2020).
  [⁶⁸Ga]Ga-DATA5m.SA.FAPi PET/CT: Specific Tracer-uptake in Focal Nodular Hyperplasia and potential Role in Liver Tumor Imaging.
  Nuklearmedizin, 59(5), 387-389. doi:10.1055/a-1164-5667

• Hofstetter M, Moon ES, D’Angelo F, Geissbühler L, Alberts I, Afshar-Oromieh A, Rösch F, Rominger A, Gourni E. (2020).
  Effect of the versatile bifunctional chelator AAZTA(5) on the radiometal labelling properties and the in vitro performance of a gastrin releasing peptide receptor antagonist.
  EJNMMI Radiopharm Chem. Nov 30 2020;5(1):29. doi:10.1186/s41181-020-00115-8

• Moon, E. S., Elvas, F., Vliegen, G., De Lombaerde, S., Vangestel, C., De Bruycker, S., Roesch, F. (2020). Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators.
  EJNMMI Radiopharm Chem, 5(1), 19. doi:10.1186/s41181-020-00102-z

• Yadav, D., Ballal, S., Yadav, M. P., Tripathi, M., Roesch, F., & Bal, C. (2020).
  Evaluation of [⁶⁸Ga]Ga-DATA-TOC for imaging of neuroendocrine tumours: comparison with [⁶⁸Ga]Ga-DOTA-NOC PET/CT.
  Eur J Nucl Med Mol Imaging, 47(4), 860-869. doi:10.1007/s00259-019-04611-1

• Yadav, M. P., Ballal, S., Meckel, M., Roesch, F., & Bal, C. (2020).
  [¹⁷⁷Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results.
  EJNMMI Res, 10(1), 130. doi:10.1186/s13550-020-00709-y

2019

• Stergiou, N., Nagel, J., Pektor, S., Heimes, A. S., Jakel, J., Brenner, W., Roesch, F., Schmitt, E. (2019).
  Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer.
  Int J Med Sci, 16(9), 1188-1198. doi:10.7150/ijms.35452

• Khawar, A., Eppard, E., Roesch, F., Ahmadzadehfar, H., Kürpig, S., Meisenheimer, M., Bundschuh, R. A. (2019).
  Biodistribution and post-therapy dosimetric analysis of [¹⁷⁷Lu]Lu-DOTA(ZOL) in patients with osteoblastic metastases: first results.
  EJNMMI Res, 9(1), 102. doi:10.1186/s13550-019-0566-x

• Khawar, A., Eppard, E., Roesch, F., Ahmadzadehfar, H., Kürpig, S., Meisenheimer, M., Bundschuh, R. A. (2019).
  Preliminary results of biodistribution and dosimetric analysis of [⁶⁸Ga]Ga-DOTA(ZOL): a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseases.
  Ann Nucl Med, 33(6), 404-413. doi:10.1007/s12149-019-01348-7